DGIdb - ABCG2 Gene Record

ABCG2 9429 Druggable Genome

Alternate Names:

9429
ATP BINDING CASSETTE SUBFAMILY G MEMBER 2 (JUNIOR BLOOD GROUP)
ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR-1
MXR1
UAQTL1
603756
74
ENSG00000118777
OTTHUMG00000130601
Q9UNQ0
ABCG2_HUMAN
ATP-BINDING CASSETTE, SUB-FAMILY G, MEMBER 2 (PLACENTA-SPECIFIC ATP- BINDING CASSETTE TRANSPORTER) (BREAST CANCER RESISTANCE PROTEIN) (MITOXANTRONE RESISTANCE ASSOCIATED PROTEIN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UNQ0]
PA390
ATP-binding cassette transporter G2
T56556
ATP-binding cassette sub-family G member 2

Gene Info:

Target Subclass	ABCG
Target Subclass	Active_transporters
Target Main Class	Transporters
Transmembrane Helix Count	5
Human Readable Name	DRUGGABLE GENOME
Gene Biotype	PROTEIN_CODING

(6 More Sources)

Gene Categories: Category Details

TRANSPORTER
ABC TRANSPORTER
DRUGGABLE GENOME

Publications:

Gupta et al., 2007, Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)., J Pharm Sci
Marchetti et al., 2008, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice., Mol. Cancer Ther.
Bauer F et al., 2010, Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor., Bioorg Med Chem
Robey et al., 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells., Clin. Cancer Res.
Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
Kobayashi H et al., 2015, Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer., Clin Lung Cancer
Lemos C et al., 2011, Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients., Pharmacogenomics
Akasaka K et al., 2010, Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer., Cancer Chemother Pharmacol
Cusatis G et al., 2006, Pharmacogenetics of ABCG2 and adverse reactions to gefitinib., J Natl Cancer Inst
Breedveld et al., 2005, The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients., Cancer Res.
Verboom MC et al., 2019, Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors., Pharmacogenomics J
Skoglund K et al., 2014, Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line., Pharmacogenet Genomics
Delord M et al., 2013, High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients., Oncotarget
Petain A et al., 2008, Population pharmacokinetics and pharmacogenetics of imatinib in children and adults., Clin Cancer Res
Ozvegy-Laczka et al., 2004, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter., Mol. Pharmacol.
Wang et al., 2007, Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2., Drug Metab. Dispos.
Allegra S et al., 2017, Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients., Pharmacogenomics
Allegra S et al., 2016, Deferasirox AUC efficacy cutoff and role of pharmacogenetics., Eur J Clin Pharmacol
Cusato J et al., 2016, Role of pharmacogenetics on deferasirox AUC and efficacy., Pharmacogenomics
Sánchez Martín A et al., 2013, Impact of pharmacogenetics on CNS side effects related to efavirenz., Pharmacogenomics
Winter E et al., 2014, Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones., J Med Chem
Xiao G et al., 2012, Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates., Drug Metab Dispos
Winter E et al., 2013, Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2., J Med Chem
Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics
Kashihara Y et al., 2017, Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., J Pharm Sci
Gotanda K et al., 2015, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol
Wiese MD et al., 2014, Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis., Pharmacogenomics J
Yamasaki Y et al., 2008, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther
Allen JD et al., 2002, A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance., Cancer Res
Lee CA et al., 2015, Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design., Drug Metab Dispos
Juvale K et al., 2013, Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2., Eur J Med Chem
Zhang et al., 2004, Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport., Pharm. Res.
Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
Pawarode et al., 2007, Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins., Cancer Chemother. Pharmacol.
Lee et al., 2005, Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein., J. Pharmacol. Exp. Ther.
De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
Kajita et al., 2006, Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats., J. Pharm. Pharmacol.
Combes S et al., 2011, Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2., J Med Chem
Chu YH et al., 2015, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma., PLoS One
Narjoz C et al., 2015, Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients., Invest New Drugs
Kim HR et al., 2013, Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients., Cancer Chemother Pharmacol
Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
Ueshima S et al., 2018, Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation., Br J Clin Pharmacol
Ueshima S et al., 2017, Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation., Pharmacogenet Genomics
Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
Allegra S et al., 2018, Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations., J Clin Pharmacol
Ho et al., 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants., Pharmacogenet. Genomics
Birmingham BK et al., 2015, Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States., Eur J Clin Pharmacol
Lee HK et al., 2013, Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients., Pharmacogenomics
Chasman DI et al., 2012, Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial., Circ Cardiovasc Genet
Hu M et al., 2010, Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients., Pharmacogenet Genomics
Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet
Tomlinson B et al., 2010, ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin., Clin Pharmacol Ther
Kitamura S et al., 2008, Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin., Drug Metab Dispos
Zhang W et al., 2006, Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males., Clin Chim Acta
Keskitalo JE et al., 2009, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin., Clin Pharmacol Ther
Li XQ et al., 2015, Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives., Eur J Med Chem
Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos
Brackman DJ et al., 2019, Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol., Clin Pharmacol Ther
Wright DFB et al., 2018, The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool., Br J Clin Pharmacol
Roberts RL et al., 2017, ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout., Pharmacogenomics J
Pick A et al., 2008, Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)., Bioorg Med Chem
Baxi SM et al., 2018, Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV., Pharmacogenomics J
Klarica Domjanović I et al., 2018, Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy., Br J Clin Pharmacol
Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
Zhou Y et al., 2015, Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients., Drug Metab Pharmacokinet
Stacy AE et al., 2013, Molecular pharmacology of ABCG2 and its role in chemoresistance., Mol Pharmacol
Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.
Roberts JK et al., 2016, Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant., Drug Metab Dispos
Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J
Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics
Warren RB et al., 2008, Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis., J Invest Dermatol
Nakagawa H et al., 2008, Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2., Biochem J

CHEMBL488910 ABCG2

Interaction Score: 3.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24611893 22266779 24304387

Sources:
DTC
CHEMBL428402 ABCG2

Interaction Score: 1.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18678495

Sources:
DTC
RETUSIN ABCG2

Interaction Score: 1.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23851114

Sources:
DTC
ELACRIDAR ABCG2

Interaction Score: 1.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22266779

Sources:
DTC PharmGKB
CHEMBL444075 ABCG2

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26197160

Sources:
DTC
APIXABAN ABCG2

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29457840 28678049

Sources:
PharmGKB
TARIQUIDAR ABCG2

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20621487

Sources:
DTC
ROSUVASTATIN ABCG2

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28322941 25630984 23930675 22331829 20679960 20207952 20130569 18617601 16784736 19474787

Sources:
PharmGKB
SILYBIN A ABCG2

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15290869

Sources:
NCI
ETRAVIRINE ABCG2

Interaction Score: 0.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
DOLUTEGRAVIR ABCG2

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28858994

Sources:
PharmGKB
DELAVIRDINE ABCG2

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
DEFERASIROX ABCG2

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28346059 27193993 27043265

Sources:
PharmGKB
VORICONAZOLE ABCG2

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17518356

Sources:
NCI
SULFASALAZINE ABCG2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28322941 25872459 24394199 18167504

Sources:
PharmGKB TTD
PRAZOSIN ABCG2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23073734

Sources:
DTC
ITRACONAZOLE ABCG2

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17518356

Sources:
NCI
EFAVIRENZ ABCG2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339 23859571

Sources:
DTC PharmGKB
NILOTINIB ABCG2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24322003

Sources:
PharmGKB
NITROFURANTOIN ABCG2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17093006

Sources:
NCI
TENOFOVIR ABCG2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28462920

Sources:
PharmGKB
CEFTRIAXONE ABCG2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29873816

Sources:
PharmGKB
LAMOTRIGINE ABCG2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791014 27610747 26213157

Sources:
PharmGKB
LEUCOVORIN ABCG2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB
ALLOPURINOL ABCG2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30924126 29341237 26810134

Sources:
PharmGKB
TOPOTECAN ABCG2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27052877

Sources:
PharmGKB
IMATINIB ABCG2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15805252 30713339 24322003 24123600 18981009 15155841

Sources:
NCI PharmGKB
PRAVASTATIN ABCG2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17622941 19842935

Sources:
NCI PharmGKB
PRASTERONE ABCG2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15448171

Sources:
NCI
ALVOCIDIB ABCG2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11205902

Sources:
NCI
KETOCONAZOLE ABCG2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17518356

Sources:
NCI
SUNITINIB ABCG2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26244574 25344452 24013576

Sources:
PharmGKB
CYCLOSPORINE ABCG2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16805961 21488686 17031644

Sources:
DTC NCI PharmGKB
CHLORPROMAZINE ABCG2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18834354

Sources:
NCI
FLUVASTATIN ABCG2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19842935

Sources:
PharmGKB
NEVIRAPINE ABCG2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
CAPECITABINE ABCG2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 20530282

Sources:
PharmGKB
OXALIPLATIN ABCG2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 20530282

Sources:
PharmGKB
METHOTREXATE ABCG2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011 27217051 25778468 21317831 20386493 18256692 18237272

Sources:
PharmGKB
GEFITINIB ABCG2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25554506 21332310 20035425 17148776

Sources:
PharmGKB
ZIDOVUDINE ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22960662

Sources:
PharmGKB
TACROLIMUS ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17031644

Sources:
NCI
IRINOTECAN ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24018773 18221820

Sources:
PharmGKB
SIMVASTATIN ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24598718 19842935

Sources:
PharmGKB
PAZOPANIB ABCG2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25504632

Sources:
PharmGKB
ERLOTINIB ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18723475

Sources:
NCI
GENISTEIN ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15290869

Sources:
NCI
LAMIVUDINE ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB
7-ETHYL-10-HYDROXYCAMPTOTHECIN ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIROLIMUS ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17031644

Sources:
NCI
ATORVASTATIN ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19474787

Sources:
PharmGKB
DAUNORUBICIN ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24021215

Sources:
PharmGKB
RUCAPARIB ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DASATINIB ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24322003

Sources:
PharmGKB
CURCUMIN ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25587128

Sources:
PharmGKB
DOCETAXEL ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
MITOXANTRONE ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
DOXORUBICIN ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11956086

Sources:
PharmGKB
PACLITAXEL ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
CYCLOPHOSPHAMIDE ABCG2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE ABCG2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000118777
- Version: 101_38
Alternate Names:

ABCG2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: Q9UNQ0
- Version: 01-August-2011
Alternate Names:

ENSG00000118777 Ensembl Gene Id

ABCG2_HUMAN Uniprot Id

ABCG2 Gene Symbol

Gene Info:

Target Subclass ABCG

Target Subclass Active_transporters

Target Main Class Transporters

Publications:

RussLampel: ENSG00000118777

Version: 26-July-2011

Alternate Names:

ABCG2 Display Id

ATP-BINDING CASSETTE, SUB-FAMILY G, MEMBER 2 (PLACENTA-SPECIFIC ATP- BINDING CASSETTE TRANSPORTER) (BREAST CANCER RESISTANCE PROTEIN) (MITOXANTRONE RESISTANCE ASSOCIATED PROTEIN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UNQ0] Description

ENSG00000118777 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

PharmGKB: ABCG2

Version: 18-August-2020

Alternate Names:

PA390 PharmGKB ID

Gene Info:

Publications:

Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics

Narjoz C et al., 2015, Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients., Invest New Drugs

Chu YH et al., 2015, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma., PLoS One

NCI: ABCG2

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Gupta et al., 2007, Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)., J Pharm Sci

Marchetti et al., 2008, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice., Mol. Cancer Ther.

Lee et al., 2005, Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein., J. Pharmacol. Exp. Ther.

DTC: ABCG2

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Xiao G et al., 2012, Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates., Drug Metab Dispos

Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother

Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos

HingoraniCasas: ENSG00000118777
- Version: 31-May-2017
Alternate Names:

ENSG00000118777 Gene Symbol

ABCG2 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: ABCG2
- Version: 01-February-2022
Alternate Names:

ABCP GO Gene Synonym

BCRP GO Gene Synonym

BCRP1 GO Gene Synonym

Gene Info:

Gene Categories:

ABC TRANSPORTER

Publications:
TTD: ATP-binding cassette transporter G2
- Version: 2020.06.01
Alternate Names:

ABCG2 TTD Gene Abbreviation

T56556 TTD Target ID

Gene Info:

Publications:
Pharos: ABCG2
- Version: 01-February-2022
Alternate Names:

ATP-binding cassette sub-family G member 2 Gene Name

Q9UNQ0 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:

ENSG00000118777	Ensembl Gene Id
ABCG2_HUMAN	Uniprot Id
ABCG2	Gene Symbol

ABCG2	Display Id
ATP-BINDING CASSETTE, SUB-FAMILY G, MEMBER 2 (PLACENTA-SPECIFIC ATP- BINDING CASSETTE TRANSPORTER) (BREAST CANCER RESISTANCE PROTEIN) (MITOXANTRONE RESISTANCE ASSOCIATED PROTEIN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UNQ0]	Description
ENSG00000118777	Ensembl Gene Id

ATP-binding cassette sub-family G member 2	Gene Name
Q9UNQ0	UniProt ID

ABCG2 Gene Record

ABCG2 9429 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24611893 22266779 24304387

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18678495

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23851114

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22266779

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26197160

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29457840 28678049

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20621487

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28322941 25630984 23930675 22331829 20679960 20207952 20130569 18617601 16784736 19474787

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15290869

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21189339

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28858994

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21189339

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28346059 27193993 27043265

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17518356

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28322941 25872459 24394199 18167504

Sources: PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23073734

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17518356

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21189339 23859571

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
24611893 22266779 24304387

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18678495

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23851114

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22266779

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26197160

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
29457840 28678049

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20621487

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
28322941 25630984 23930675 22331829 20679960 20207952 20130569 18617601 16784736 19474787

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15290869

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21189339

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
28858994

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21189339

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
28346059 27193993 27043265

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17518356

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
28322941 25872459 24394199 18167504

Sources:
PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
23073734

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17518356

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21189339 23859571

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24322003

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17093006

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
28462920

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29873816

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29791014 27610747 26213157

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30924126 29341237 26810134

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27052877

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15805252 30713339 24322003 24123600 18981009 15155841